Imunon

IMNN · NASDAQ

$1.01+$0.02 (+2.03%)TodayMarket closed · Oct 20, 4:00 PM ET

Prev close $0.985

Latest news

Press releaseSep 29, 8:00 AM ETGlobe Newswire
IMUNON Converts $1.2 Million of Debt-to-Equity
Press releaseSep 24, 8:05 AM ETGlobe Newswire
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
Press releaseSep 22, 8:05 AM ETGlobe Newswire
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
NewsSep 10, 9:31 AM ET
IMUNON Enters Into CRADA With National Cancer Institute To Advance DNA-Based IL‑12 Immunotherapy IMNN‑001
Press releaseSep 10, 9:30 AM ETGlobe Newswire
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
NewsSep 10, 8:06 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseSep 9, 8:30 AM ETGlobe Newswire
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
Press releaseAug 26, 8:30 AM ETGlobe Newswire
IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
Press releaseAug 11, 8:00 AM ETGlobe Newswire
IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update
NewsAug 7, 5:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
Press releaseAug 4, 8:00 AM ETGlobe Newswire
IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
Press releaseJul 30, 9:00 AM ETGlobe Newswire
IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
NewsJul 30, 8:30 AM ETVandana Singh
EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study
NewsJul 21, 8:30 AM ETVandana Singh
Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients
Press releaseJun 22, 4:15 PM ETGlobe Newswire
IMUNON to Present at the Life Sciences Investor Forum on June 25th
NewsMay 12, 11:54 AM ET
Imunon Reports Q1 2026 Results: Full Earnings Call Transcript
Press releaseMay 12, 8:00 AM ETGlobe Newswire
IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update
NewsMay 12, 7:11 AM ET
Earnings Scheduled For May 12, 2026
Press releaseMay 5, 8:30 AM ETGlobe Newswire
IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
NewsApr 6, 8:05 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsMar 31, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseMar 31, 8:00 AM ETGlobe Newswire
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
NewsMar 31, 7:11 AM ET
Earnings Scheduled For March 31, 2026
NewsMar 25, 11:11 AM ET
Watching Imunon; Zacks Small-Cap Research Gives Stock $33 Price Valuation
Press releaseMar 24, 8:00 AM ETGlobe Newswire
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
Press releaseDec 30, 8:30 AM ETGlobe Newswire
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
Press releaseNov 13, 7:45 AM ETGlobe Newswire
IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update
NewsNov 13, 6:11 AM ET
Earnings Scheduled For November 13, 2025
NewsNov 12, 12:03 PM ET
Exploring Imunon's Earnings Expectations
Press releaseNov 10, 1:30 PM ETGlobe Newswire
IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
Press releaseNov 10, 7:30 AM ETGlobe Newswire
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer
NewsNov 10, 7:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
Press releaseNov 7, 8:05 AM ETGlobe Newswire
IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
Press releaseNov 6, 8:05 AM ETGlobe Newswire
IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025
Press releaseNov 4, 8:05 AM ETGlobe Newswire
IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
Press releaseOct 30, 8:00 AM ETGlobe Newswire
IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting
Press releaseOct 23, 10:01 AM ETGlobe Newswire
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
Press releaseOct 20, 8:05 AM ETGlobe Newswire
IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
Press releaseOct 17, 8:10 AM ETGlobe Newswire
IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
Press releaseOct 14, 8:20 AM ETGlobe Newswire
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
Press releaseSep 22, 8:05 AM ETGlobe Newswire
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
Press releaseSep 19, 8:05 AM ETGlobe Newswire
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
Press releaseSep 2, 8:05 AM ETGlobe Newswire
IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Press releaseAug 28, 8:05 AM ETGlobe Newswire
IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
Press releaseAug 5, 4:00 PM ETGlobe Newswire
IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
Press releaseAug 5, 8:00 AM ETGlobe Newswire
IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

IMUNON Converts $1.2 Million of Debt-to-Equity

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

IMUNON Enters Into CRADA With National Cancer Institute To Advance DNA-Based IL‑12 Immunotherapy IMNN‑001

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

12 Health Care Stocks Moving In Thursday's Pre-Market Session

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

12 Health Care Stocks Moving In Friday's After-Market Session

IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026

IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study

Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients

IMUNON to Present at the Life Sciences Investor Forum on June 25th

Imunon Reports Q1 2026 Results: Full Earnings Call Transcript

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

Earnings Scheduled For May 12, 2026

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

Earnings Scheduled For March 31, 2026

Watching Imunon; Zacks Small-Cap Research Gives Stock $33 Price Valuation

IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

Earnings Scheduled For November 13, 2025

Exploring Imunon's Earnings Expectations

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

12 Health Care Stocks Moving In Monday's Pre-Market Session

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update